Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-143

Seriously like to see this moment of clarity countered;

What has happened is this (apart from the very obvious), Admedus has been given two years of its current revenue in ‘advance’ to keep lights on, future revenue will be a manufactory royalty (?) plus revenue from hitting certain milestones, in effect, best case scenario a further 12 mill.

Likely hood of meeting agreement terms, .... 1 to 5??,

Most pertinent, imo, is the likelihood and effectiveness of the new entity to nearly triple what Admedus could manage (11 mill) for that goal up to 3.7 mill, 1.8 mill if they can double what Admedus received, first year.

Second year, a massive four fold of 11 mill to receive its 3.73 mill.

Figure of 12 mill ‘seems’ a lot, until you take into consideration what future outgoings will equate too.

With this ‘breathing’ space most definitely needs to come that TAVR deal in a very timely manner, market reaction to this situation is a ‘watch and observe’.

What wessomart said; this company seriously need to reduce its massive outgoings right now!

Not out of the woods yet, imho.